Stock Research for ABSCF

ABSCF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ABSCF Stock Chart & Research Data

The ABSCF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABSCF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABSCF Due diligence Resources & Stock Charts

The ABSCF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABSCF Detailed Price Forecast - CNN Money CNN View ABSCF Detailed Summary - Google Finance
Yahoo View ABSCF Detailed Summary - Yahoo! Finance Zacks View ABSCF Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ABSCF Trends & Analysis - Trade-Ideas Barrons View ABSCF Major Holders - Barrons
NASDAQ View ABSCF Call Transcripts - NASDAQ Seeking View ABSCF Breaking News & Analysis - Seeking Alpha
Spotlight View ABSCF Annual Report - CompanySpotlight.com OTC Report View ABSCF OTC Short Report - OTCShortReport.com
TradeKing View ABSCF Fundamentals - TradeKing Charts View ABSCF SEC Filings - Bar Chart
WSJ View Historical Prices for ABSCF - The WSJ Morningstar View Performance/Total Return for ABSCF - Morningstar
MarketWatch View the Analyst Estimates for ABSCF - MarketWatch CNBC View the Earnings History for ABSCF - CNBC
StockMarketWatch View the ABSCF Earnings - StockMarketWatch MacroAxis View ABSCF Buy or Sell Recommendations - MacroAxis
Bullish View the ABSCF Bullish Patterns - American Bulls Short Pains View ABSCF Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ABSCF Stock Mentions - StockTwits PennyStocks View ABSCF Stock Mentions - PennyStockTweets
Twitter View ABSCF Stock Mentions - Twitter Invest Hub View ABSCF Investment Forum News - Investor Hub
Yahoo View ABSCF Stock Mentions - Yahoo! Message Board Seeking Alpha View ABSCF Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ABSCF - SECform4.com Insider Cow View Insider Transactions for ABSCF - Insider Cow
CNBC View ABSCF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABSCF - OTC Markets
Yahoo View Insider Transactions for ABSCF - Yahoo! Finance NASDAQ View Institutional Holdings for ABSCF - NASDAQ


Stock Charts

FinViz View ABSCF Stock Insight & Charts - FinViz.com StockCharts View ABSCF Investment Charts - StockCharts.com
BarChart View ABSCF Stock Overview & Charts - BarChart Trading View View ABSCF User Generated Charts - Trading View




Latest Financial News for ABSCF


AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
Posted on Wednesday April 03, 2024

PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED ELIGIBILITY FOR RECONSIDERATION REQUEST FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Paris, 3 April, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS). The reconsideration process will re-examine, with new assessors, the decision based on information that was included in the origina


AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
Posted on Wednesday March 13, 2024

PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS Paris, March 13, 2024, 12.45pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of new preclinical results for masitinib in neurodegenerative diseases (NDD). Findings have been published on the


AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
Posted on Thursday March 07, 2024

PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT Paris, March 7, 2024, 3pm CET AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development. The webcast presentation is available on the company’s website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/ The presentation covered four topics: Status of condi


AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
Posted on Wednesday March 06, 2024

PRESS RELEASE TWO NEW FINANCIAL ANALYSIS FIRMS INITIATE COVERAGE OF AB SCIENCE Paris, March 6, 2024, 8.15pm CET AB Science SA (Euronext - FR0010557264 - AB) announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated the coverage of the Company. DNA Finance estimates that AB Science stands out as a compelling investment opportunity in the biotech sector. In Extenso has initiated a strong buy opinion on the share. These new coverages aim to strengthen the AB Sc


Stock Market & Investing Books

Enter a stock symbol to view the stock details.